Aurora kinase A (AURKA) promotes the progression and imatinib resistance of advanced gastrointestinal stromal tumors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2867
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Aurora kinase A (AURKA) promotes the progression and imatinib resistance of advanced gastrointestinal stromal tumors ; volume:21 ; number:1 ; day:31 ; month:7 ; year:2021 ; pages:1-13 ; date:12.2021
Cancer cell international ; 21, Heft 1 (31.7.2021), 1-13, 12.2021
- Urheber
-
Cheng, Xiaobin
Wang, Jinhai
Lu, Sen
Fan, Weina
Wang, Weilin
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12935-021-02111-7
- URN
-
urn:nbn:de:101:1-2021102822020515140615
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cheng, Xiaobin
- Wang, Jinhai
- Lu, Sen
- Fan, Weina
- Wang, Weilin
- SpringerLink (Online service)
Ähnliche Objekte (12)
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy
Imatinib-Resistant Gastrointestinal Stromal Tumor Presenting as a Large Abdominal Mass
Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors
A rectal gastrointestinal stromal tumor—a plea for neoadjuvant imatinib and TAMIS
Severe esophagitis in a patient with gastrointestinal stromal tumor treated with imatinib
Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
Imatinib use for gastrointestinal stromal tumors among older patients in Japan and Taiwan
Genome-scale CRISPR-Cas9 knockout screening in gastrointestinal stromal tumor with Imatinib resistance
Imatinib induces ferroptosis in gastrointestinal stromal tumors by promoting STUB1-mediated GPX4 ubiquitination
Gynecomastia during imatinib mesylate treatment for gastrointestinal stromal tumor: a rare adverse event
TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy
Imatinib-Resistant Gastrointestinal Stromal Tumor Presenting as a Large Abdominal Mass
Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors
A rectal gastrointestinal stromal tumor—a plea for neoadjuvant imatinib and TAMIS
Severe esophagitis in a patient with gastrointestinal stromal tumor treated with imatinib
Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
Imatinib use for gastrointestinal stromal tumors among older patients in Japan and Taiwan
Genome-scale CRISPR-Cas9 knockout screening in gastrointestinal stromal tumor with Imatinib resistance
Imatinib induces ferroptosis in gastrointestinal stromal tumors by promoting STUB1-mediated GPX4 ubiquitination
Gynecomastia during imatinib mesylate treatment for gastrointestinal stromal tumor: a rare adverse event
TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy
Imatinib-Resistant Gastrointestinal Stromal Tumor Presenting as a Large Abdominal Mass
Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors
A rectal gastrointestinal stromal tumor—a plea for neoadjuvant imatinib and TAMIS
Severe esophagitis in a patient with gastrointestinal stromal tumor treated with imatinib
Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
Imatinib use for gastrointestinal stromal tumors among older patients in Japan and Taiwan
Genome-scale CRISPR-Cas9 knockout screening in gastrointestinal stromal tumor with Imatinib resistance
Imatinib induces ferroptosis in gastrointestinal stromal tumors by promoting STUB1-mediated GPX4 ubiquitination
Gynecomastia during imatinib mesylate treatment for gastrointestinal stromal tumor: a rare adverse event